Investigating the role of vitamin B6 in treating acute myeloid leukemia
Official title: Characterizing vitamin B6 pathway dependency in acute myeloid leukemia
Funded at Cold Spring Harbor Laboratory · NIH-11002269 · Data updated 2026-11-12
This study is looking at how vitamin B6 helps the growth of acute myeloid leukemia (AML) cells, with the hope of finding new ways to treat this fast-growing blood cancer and improve outcomes for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project start | January 5, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $395,280 |
| NIH project number | 5R37CA276938-03 |
| Project ID | NIH-11002269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those who have not responded well to standard chemotherapy.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on acute myeloid leukemia (AML), a severe blood cancer that progresses rapidly and has limited treatment options. The study aims to explore how the vitamin B6 pathway is crucial for the growth of AML cells, potentially identifying new therapeutic targets. By understanding the metabolic dependencies of AML on vitamin B6, the researchers hope to develop more effective combination therapies that could improve patient outcomes. The approach involves examining key enzymes in the vitamin B6 metabolic pathway that are essential for AML cell proliferation.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with acute myeloid leukemia.
How similar studies have gone: While the specific focus on the vitamin B6 pathway in AML is novel, similar metabolic targeting approaches have shown promise in other cancers.
Where this research is happening
-
Cold Spring Harbor Laboratory
Cold Spring Harbor, United States Active
Researchers
- Principal investigator: Zhang, Lingbo — Cold Spring Harbor Laboratory
- Study coordinator: Zhang, Lingbo
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.